Form 4: Intra-Cellular Therapies Executive Exercises Stock Options

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., reports the exercise of stock options resulting in the acquisition and disposal of common stock.

Summary

• On March 6, 2024, Mark Neumann, the EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., executed transactions involving the company's stock.
• Neumann exercised restricted stock units, converting them into 13,132 shares of common stock.
• Following the reported transaction, Neumann directly owns 42,832 shares of Intra-Cellular Therapies common stock.
• The exercised restricted stock units were part of a grant from March 6, 2023, which vested in three equal annual installments.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects a standard transaction by an executive exercising vested stock options. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.

Key Dates